ArticlePharmacoepidemiology and drug safety2024
Generating Real-World Evidence From the Excellence Network in Rheumatology.
Article in Pharmacoepidemiology and drug safety, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Treatment Sequencing and Line of Therapy for Biologics and JAK Inhibitors in Patients With Rheumatoid Arthritis: Implications for Design and Uptake of New Drugs and Predictive Biomarker Diagnostics.Arthritis care & research · 2026Article
- Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug.Arthritis care & research · 2026Article
- Opportunities and Challenges in Using National EHR Networks for AI in Learning Health Systems.Learning health systems · 2026Article
- Evaluating a Smartphone App-Based Module for Joint Self-Assessment as a Complementary Tool in Rheumatoid Arthritis Remote Disease Management.ACR open rheumatology · 2026Article
- Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data.RMD open · 2026Article
- Impact of non-serious infections on medication interruptions, quality of life, and disease flares in patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThe Excellence Network in RheumatoloGY (ENRGY) was founded in 2021 and encompasses data from more than 700 private practice rheumatology providers throughout the United States, forming a practice-based research network (PBRN).
methodsElectronic health record (EHR) data from participating practices are aggregated, including structured data (e.g., clinical assessments) and unstructured data from two different EHR platforms. Targeted data quality efforts ensure capture of high-quality clinical data and reduce missingness. ENRGY network membership also provides participating sites access to technology services that enhance patient care. Centralized ethics approval and pre-existing legal agreements along with electronic tools to curate data and contact eligible study participants improves efficiency of multi-center prospective studies.
resultsThe ENRGY data warehouse includes linked administrative claims data for commercial and government-provided insurance (31% of patients linked to commercial claims) and patient-generated health data from both in-office and out-of-office settings via a smartphone app as well as biosensor data. ENRGY data and infrastructure can be employed to identify the highest yield sites for prospective studies; identify patients meeting study eligibility criteria; pre-screen individual patient's willingness to participate in specific studies; centralize study data monitoring; and assist in the conduct of prospective studies.
conclusionENRGY data have been used to generate a growing number of scientific publications and may serve as a model for PBRNs in other specialties seeking to harness the potential of data linkages, patient-generated data capture, and centralized study infrastructure for observational and interventional research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.